UK sets up new Vaccine Taskforce as COVID-19 death toll hits 14,576

Image
Press Trust of India London
Last Updated : Apr 17 2020 | 10:46 PM IST

The UK government on Friday announced the creation of a Vaccine Taskforce to urgently find a coronavirus vaccine and prepare industry to manufacture it at scale once it is developed as the COVID-19 death toll in the country rose by a further 847 to hit 14,576.

Addressing the daily Downing Street briefing, UK Business Secretary Alok Sharma said the new taskforce, led by the government's Chief Scientific Adviser Sir Patrick Vallance, is a collaboration between business and industry and academia and is aimed at coordinating efforts to discover a vaccine, funnel resources and support to industry and research institutions and review regulations to remove any blocks in scaling it up.

"We cannot put a date on when we will get a vaccine. But we live in a country with a rich history of pioneering science, and with the government backing our scientists, we have the best chance to do this as quickly as possible," said the Indian-origin Cabinet minister.

Sharma also announced 21 new research projects to receive funds from a 14 million pounds government pot for the development of treatments and vaccines.

He said: UK scientists are working as fast as they can to find a vaccine that fights coronavirus, saving and protecting people's lives. We stand firmly behind them in their efforts.

The Vaccine Taskforce is key to coordinating efforts to rapidly accelerate the development and manufacture of a potential new vaccine, so we can make sure it is widely available to patients as soon as possible.

Under details of some of the scientific work ongoing to combat the spread of the deadly virus, one new project is led by the University of Oxford to trial an anti-malarial drug, believed to have anti-inflammatory properties, to determine whether it could diminish the effects of COVID-19 on people in high risk groups.

General Practitioner (GP) surgeries across the UK have been invited to take part in the groundbreaking trial, to ascertain whether it could reduce the need for affected patients to go to hospital and speed up their recovery.

Other projects receiving vital government funding under the new taskforce include an Imperial College London initiative testing a vaccine against coronavirus that aims for the body to produce more protective antibodies and Public Health England developing a new antibody that could offer protection against infection and disease progression of coronavirus.

Public Health England is also studying how COVID-19 can be transmitted from person-to-person by determining how long it can survive in the air and on different materials found in hospitals and households like fabric, plastics, metals and ceramics.

The UK has already pledged 250 million pounds to the international effort to develop a coronavirus vaccine under the Coalition for Epidemic Preparedness Innovations (CEPI).

The latest announcement aims to make the UK a leader in clinical vaccine testing and manufacturing, building on existing research and development expertise.

UK Health Secretary Matt Hancock said: We're doing everything possible to save lives and beat this disease, and that includes working flat out with businesses, researchers and industry to find a vaccine as quickly as possible.

The UK is world-leading in developing vaccines. We are the biggest contributor to the global effort and preparing to ensure we can manufacture vaccines here at home as soon as practically possible.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 17 2020 | 10:46 PM IST

Next Story